Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses

PLoS One. 2014 Aug 22;9(8):e105891. doi: 10.1371/journal.pone.0105891. eCollection 2014.

Abstract

To clarify pharmacokinetic-pharmacodynamic (PK-PD) factors associated with the over-anticoagulation response in Asians during warfarin induction therapy, population PK-PD analyses were conducted in an attempt to predict the time-courses of the plasma S-warfarin concentration, Cp(S), and coagulation and anti-coagulation (INR) responses. In 99 Chinese patients we analyzed the relationships between dose and Cp(S) to estimate the clearance of S-warfarin, CL(S), and that between Cp(S) and the normal prothrombin concentration (NPT) as a coagulation marker for estimation of IC50. We also analyzed the non-linear relationship between NPT inhibition and the increase in INR to derive the non-linear index λ. Population analyses accurately predicted the time-courses of Cp(S), NPT and INR. Multivariate analysis showed that CYP2C9*3 mutation and body surface area were predictors of CL(S), that VKORC1 and CYP4F2 polymorphisms were predictors of IC50, and that baseline NPT was a predictor of λ. CL(S) and λ were significantly lower in patients with INR≥4 than in those with INR<4 (190 mL/h vs 265 mL/h, P<0.01 and 3.2 vs 3.7, P<0.01, respectively). Finally, logistic regression analysis revealed that CL(S), ALT and hypertension contributed significantly to INR≥4. All these results indicate that factors associated with the reduced metabolic activity of warfarin represented by CL(S), might be critical determinants of the over-anticoagulation response during warfarin initiation in Asians.

Trial registration: ClinicalTrials.gov NCT02065388.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Anticoagulants / pharmacokinetics
  • Anticoagulants / therapeutic use*
  • Asian People
  • Cytochrome P-450 CYP2C9 / genetics*
  • Cytochrome P-450 Enzyme System / genetics
  • Cytochrome P450 Family 4
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Mutation
  • Polymorphism, Genetic
  • Treatment Outcome
  • Vitamin K Epoxide Reductases / genetics*
  • Warfarin / blood
  • Warfarin / pharmacokinetics*
  • Warfarin / therapeutic use*

Substances

  • Anticoagulants
  • Warfarin
  • Cytochrome P-450 Enzyme System
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Cytochrome P450 Family 4
  • CYP4F2 protein, human
  • VKORC1 protein, human
  • Vitamin K Epoxide Reductases

Associated data

  • ClinicalTrials.gov/NCT02065388